Phase III, double-blind, randomized, placebo-controlled trial of FavID (Id/KLH) [mitumprotimut T] and GM-CSF following CHOP/rituximab [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] as first-line therapy in subjects with high-intermediate and high-risk diffuse large B-cell lymphoma
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2007
At a glance
- Drugs Mitumprotimut T (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors MMRGlobal
- 04 Jun 2007 Status changed from recruiting to suspended.
- 06 Nov 2006 New trial record.